Mr. Todd Shapiro reports

RED LIGHT HOLLAND ANNOUNCES FILAMENT HEALTH'S LARGEST-EVER MANUFACTURING RUN OF PEX010, THE STANDARDIZED AND PATENTED NATURAL PSILOCYBIN DRUG CANDIDATE TRUSTED ACROSS 80+ STUDIES GLOBALLY, NOW OFFERING THE WIDEST STANDARDIZED DOSING RANGE, FROM 0.5 MG TO 25 MG

Following Red Light Holland Corp.'s acquisition of Filament Health Corp., Red Light has expanded its pharmaceutical-grade manufacturing, regulatory and clinical research capabilities, supporting the advancement of naturally derived psilocybin development and Filament's patented botanical drug candidate, PEX010.

The company is pleased to announce that Filament has commenced the largest manufacturing run in its history of PEX010, its standardized, patented botanical psilocybin drug candidate. The expanded production run is designed to meet sustained global demand from academic and clinical research institutions and to broaden the range of standardized doses available to investigators worldwide.

As part of this run, Filament is introducing a new 0.5-milligram dose alongside its existing one-, five- and 25-milligram strengths, giving researchers a standardized range of 0.5, one, five and 25 mg from a single drug candidate, from subhallucinogenic microdosing through to full therapeutic doses. Standardized natural psilocybin offerings elsewhere have generally been confined to a narrow band of mid-range doses whereas every PEX010 strength is drawn from the same drug product and produced to the same specification, so that a 0.5-milligram dose and a 25-milligram dose share an identical composition, purity and stability profile, differing only in strength rather than in batch or method.

PEX010 is produced using Filament's proprietary extraction, purification and stabilization methods, which deliver a potent yet standardized and patented botanical drug product with consistent composition across every dose, every study and every research site. That consistency is protected by a broad international patent portfolio and backed by a demonstrated 36-month shelf life. PEX010 offers reproducibility at scale, a composition that does not drift from one production run to the next, allowing investigators to attribute their findings to the compound itself rather than to batch-to-batch variation.

This development reflects continued demand for pharmaceutical-grade, naturally derived psilocybin and the expanding role of Filament's PEX010 drug candidate in academic and clinical research while reinforcing the operational and quality systems that support reliable global supply. PEX010 has been supplied to more than 80 academic and philanthropic research studies worldwide, including trials at leading institutions such as Imperial College, Johns Hopkins University, the University of California, San Francisco and McGill University.

The new 0.5-milligram dose responds directly to real-world evidence. An analysis of consensual, anonymized data from the company's iMicroapp by Prof. David Nutt and Drug Science, the United Kingdom's leading independent scientific body on drugs, indicates many people were microdosing doses below one milligram. Producing a standardized, precisely measured 0.5-milligram dose is intended to bring this widely practised but poorly characterized low-dose range into a controlled, reproducible format, supporting safer accessibility and enabling prescribers and clinical trial investigators to study and scale microdosing research with confidence.

"This production run is about widening access, which was always our mission," said Todd Shapiro, chief executive officer and director of Red Light. "Our consensual, real-world data tells us that a meaningful share of people microdose at the very low end, below an estimated one milligram, yet, until now, there has been no standardized, precisely measured product at that level for prescribers and clinical trials to work with. By manufacturing a true 0.5-milligram dose to the same patented standard as every other strength of PEX010, we are giving researchers the tools to study microdosing rigorously and giving the field a credible path to scale it safely."

On April 30, 2026, Red Light completed its previously announced acquisition of Filament Health, including its portfolio of 76 issued patents across 13 patent families and its lead drug candidate, PEX010, creating a global leader in psychedelic drug development, commercialization and distribution.

About Red Light Holland Corp.

Red Light Holland is an Ontario-based organization advancing a focused strategy within the legal psychedelic sector, centred on consensual data collection and research and development initiatives designed to expand naturally occurring drug development, understanding of psilocybin use and consumer experiences. In parallel, the company operates commercial activities across Europe and North America, including psilocybin truffle sales in the Dutch legal market and mushroom home grow kits offered through business-to-business and direct-to-consumer channels, in compliance with applicable laws.

We seek Safe Harbor.